Multivariate analysis of transplant outcomes
| . | LFS . | OS . | Incidence of relapse . | Non-relapse mortality . |
|---|---|---|---|---|
| Age (10-y increase) | 1.09 (0.99-1.21), P = .0812 | 1.17 (1.05-1.3), P = .0042 | 0.95 (0.84-1.07), P = .3871 | 1.41 (1.18-1.68), P = .0002 |
| Cytogenetic risk: poor vs intermediate | 1.68 (1.4-2.03), P < .0001 | 1.71 (1.41-2.07), P < .0001 | 2.06 (1.63-2.6), P < .0001 | 1.23 (0.9-1.68), P = .1964 |
| Year of HCT (1-y increase) | 1.02 (0.99-1.05), P = .1439 | 1.01 (0.98-1.04), P = .4641 | 1.04 (1.01-1.08), P = .0252 | 0.98 (0.94-1.03), P = .5343 |
| Female donor to male patient vs other | 0.98 (0.79-1.23), P = .8942 | 1.04 (0.82-1.31), P = .7596 | 0.79 (0.58-1.06), P = .117 | 1.36 (0.96-1.93), P = .079 |
| URD 10/10 vs MSD | 0.84 (0.66-1.07), P = .1606 | 1.04 (0.81-1.34), P = .7394 | 0.63 (0.47-0.86), P = .0029 | 1.36 (0.91-2.03), P = .1302 |
| URD 9/10 vs IMSD | 1.1 (0.8-1.5), P = .5561 | 1.32 (0.95-1.84), P = .0938 | 0.81 (0.54-1.21), P = .3015 | 1.86 (1.13-3.06), P = .0154 |
| CMV patient: positive vs negative | 1.14 (0.93-1.4), P = .2154 | 1.14 (0.92-1.41), P = .2405 | 1.05 (0.81-1.36), P = .7273 | 1.3 (0.93-1.81), P = .1219 |
| CMV donor: positive vs negative | 1 (0.82-1.21), P = .974 | 1.05 (0.86-1.28), P = .6647 | 1.13 (0.89-1.45), P = .3129 | 0.84 (0.62-1.13), P = .2492 |
| Cell source: PB vs BM | 0.88 (0.64-1.2), P = .4076 | 0.78 (0.57-1.07), P = .1202 | 0.89 (0.59-1.32), P = .5536 | 0.87 (0.53-1.43), P = .5891 |
| Disease status at HCT: CR2 vs CR1 | 1.21 (0.79-1.85), P = .3758 | 1.31 (0.85-2.03), P = .2166 | 1.18 (0.66-2.1), P = .5834 | 1.18 (0.64-2.2), P = .5986 |
| Disease status at HCT: active vs CR1 | 1.48 (1.22-1.78), P < .0001 | 1.43 (1.17-1.74), P = .0005 | 1.69 (1.33-2.15), P < .0001 | 1.19 (0.88-1.62), P = .2638 |
| TCD: ATG/alemtuzumab vs no | 0.95 (0.74-1.21), P = .6648 | 0.91 (0.71-1.18), P = .4741 | 0.95 (0.7-1.29), P = .7492 | 0.95 (0.64-1.41), P = .7959 |
| RIC vs MAC (6 mo before HCT) | 1.1 (0.84-1.43), P = .4868 | 0.89 (0.66-1.2), P = .4423 | 1.34 (0.96-1.88), P = .0874 | 0.8 (0.52-1.21), P = .2856 |
| RIC vs MAC (6 mo after HCT) | 1.43 (1.05-1.94), P = .0243 | 1.53 (1.14-2.05), P = .005 | 1.79 (1.19-2.68), P = .0052 | 1 (0.62-1.6), P = .9862 |
| . | LFS . | OS . | Incidence of relapse . | Non-relapse mortality . |
|---|---|---|---|---|
| Age (10-y increase) | 1.09 (0.99-1.21), P = .0812 | 1.17 (1.05-1.3), P = .0042 | 0.95 (0.84-1.07), P = .3871 | 1.41 (1.18-1.68), P = .0002 |
| Cytogenetic risk: poor vs intermediate | 1.68 (1.4-2.03), P < .0001 | 1.71 (1.41-2.07), P < .0001 | 2.06 (1.63-2.6), P < .0001 | 1.23 (0.9-1.68), P = .1964 |
| Year of HCT (1-y increase) | 1.02 (0.99-1.05), P = .1439 | 1.01 (0.98-1.04), P = .4641 | 1.04 (1.01-1.08), P = .0252 | 0.98 (0.94-1.03), P = .5343 |
| Female donor to male patient vs other | 0.98 (0.79-1.23), P = .8942 | 1.04 (0.82-1.31), P = .7596 | 0.79 (0.58-1.06), P = .117 | 1.36 (0.96-1.93), P = .079 |
| URD 10/10 vs MSD | 0.84 (0.66-1.07), P = .1606 | 1.04 (0.81-1.34), P = .7394 | 0.63 (0.47-0.86), P = .0029 | 1.36 (0.91-2.03), P = .1302 |
| URD 9/10 vs IMSD | 1.1 (0.8-1.5), P = .5561 | 1.32 (0.95-1.84), P = .0938 | 0.81 (0.54-1.21), P = .3015 | 1.86 (1.13-3.06), P = .0154 |
| CMV patient: positive vs negative | 1.14 (0.93-1.4), P = .2154 | 1.14 (0.92-1.41), P = .2405 | 1.05 (0.81-1.36), P = .7273 | 1.3 (0.93-1.81), P = .1219 |
| CMV donor: positive vs negative | 1 (0.82-1.21), P = .974 | 1.05 (0.86-1.28), P = .6647 | 1.13 (0.89-1.45), P = .3129 | 0.84 (0.62-1.13), P = .2492 |
| Cell source: PB vs BM | 0.88 (0.64-1.2), P = .4076 | 0.78 (0.57-1.07), P = .1202 | 0.89 (0.59-1.32), P = .5536 | 0.87 (0.53-1.43), P = .5891 |
| Disease status at HCT: CR2 vs CR1 | 1.21 (0.79-1.85), P = .3758 | 1.31 (0.85-2.03), P = .2166 | 1.18 (0.66-2.1), P = .5834 | 1.18 (0.64-2.2), P = .5986 |
| Disease status at HCT: active vs CR1 | 1.48 (1.22-1.78), P < .0001 | 1.43 (1.17-1.74), P = .0005 | 1.69 (1.33-2.15), P < .0001 | 1.19 (0.88-1.62), P = .2638 |
| TCD: ATG/alemtuzumab vs no | 0.95 (0.74-1.21), P = .6648 | 0.91 (0.71-1.18), P = .4741 | 0.95 (0.7-1.29), P = .7492 | 0.95 (0.64-1.41), P = .7959 |
| RIC vs MAC (6 mo before HCT) | 1.1 (0.84-1.43), P = .4868 | 0.89 (0.66-1.2), P = .4423 | 1.34 (0.96-1.88), P = .0874 | 0.8 (0.52-1.21), P = .2856 |
| RIC vs MAC (6 mo after HCT) | 1.43 (1.05-1.94), P = .0243 | 1.53 (1.14-2.05), P = .005 | 1.79 (1.19-2.68), P = .0052 | 1 (0.62-1.6), P = .9862 |